title: The Provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome.
abstract: OBJECTIVE
  To compare the hospital course and clinical outcome of preterm infants with respiratory distress syndrome treated with surfactant and managed with high-frequency oscillatory ventilation (HFOV) or conventional mechanical ventilation (CV) as their primary mode of ventilator support.
  
  
  METHODS
  A prospective randomized clinical trial.
  
  
  METHODS
  Three community-based level III neonatal intensive care units.
  
  
  METHODS
  A total of 125 neonates who were 35 weeks or less estimated gestation requiring intubation and assisted ventilation for respiratory distress syndrome with arterial to alveolar oxygen ratio less than .50.
  
  
  METHODS
  Patients were randomized to continue CV (61 patients) or be changed to HFOV (64 patients) after exogenous surfactant administration (100 mg/kg). HFOV was used in a strategy to promote lung recruitment and maintain lung volume. Protocol respiratory care guidelines were followed; otherwise routine care was provided by each neonatal intensive care unit.
  
  
  RESULTS
  No differences were noted in demographic features between the two study groups. The study population birth weight was 1.51 +/- .47 kg (mean +/- SD), gestational age was 30.9 +/- 2.5 weeks, and study entry age was 2 to 3 hours. Patients randomized to HFOV demonstrated the following significant findings compared with CV-treated patients: vasopressor support was less intensive; surfactant redosing was not as frequent; oxygenation improved more rapidly and remained higher during the first 7 days; fewer infants required prolonged supplemental oxygen or ventilator support; treatment failure was reduced; more patients survived without chronic lung disease at 30 days; need for continuous supplemental oxygen at discharge was less; frequency of necrotizing enterocolitis illness was lower; there were fewer abnormal hearing tests; and hospital costs were decreased. No differences were seen between the two study groups in the frequency or severity of patent ductus arteriosus, air leak, retinopathy of prematurity, or intraventricular hemorrhage. Length of hospital stay and survival to discharge were similar for HFOV- and CV-treated infants.
  
  
  CONCLUSIONS
  When used early with a lung recruitment strategy, HFOV after surfactant replacement resulted in clinical outcomes consistent with a reduction in both acute and chronic lung injury. Benefit was evident for preterm infants both less than or equal to 1 kg and more than 1 kg. In addition, early HFOV treatment may have had a more global effect on patient health throughout the hospitalization, resulting in reduced morbidity and decreased health care cost.
authors.affiliation: Utah Valley Regional Medical Center, Provo 84604, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Gerstmann
authors.forename: S D
authors.initials: SD
authors.lastname: Minton
authors.forename: R A
authors.initials: RA
authors.lastname: Stoddard
authors.forename: K S
authors.initials: KS
authors.lastname: Meredith
authors.forename: F
authors.initials: F
authors.lastname: Monaco
authors.forename: J M
authors.initials: JM
authors.lastname: Bertrand
authors.forename: O
authors.initials: O
authors.lastname: Battisti
authors.forename: J P
authors.initials: JP
authors.lastname: Langhendries
authors.forename: A
authors.initials: A
authors.lastname: Francois
authors.forename: R H
authors.initials: RH
authors.lastname: Clark
mesh_terms: D004868:Equipment Failure; D005260:Female; D006612:High-Frequency Ventilation / Q000295:instrumentation; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D008297:Male; D017063:Outcome Assessment, Health Care; D011659:Pulmonary Gas Exchange; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000191:economics / Q000628:therapy*; D012178:Retinopathy of Prematurity / Q000209:etiology; D013501:Surface-Active Agents / Q000627:therapeutic use*; D017211:Treatment Failure; D014589:Utah
chemical_list: D013501:Surface-Active Agents